Maryland Panel Caps Ozempic Price at $274, Setting Precedent for Drug Affordability

Overview of the Maryland Drug Affordability Board's Latest Move

The Maryland Prescription Drug Affordability Board has taken a significant step to rein in the cost of a widely used diabetes medication. The board voted to establish an upper payment limit for Ozempic, a type 2 diabetes treatment from Novo Nordisk. This marks the second time the panel has utilized its authority to cap drug prices, following a similar action on another medication in recent weeks. The decision aims to reduce financial burdens for state and local government health plans, with the price cap set to take effect by January 2027.

Maryland Panel Caps Ozempic Price at $274, Setting Precedent for Drug Affordability — Source: www.statnews.com

How the Maryland Prescription Drug Affordability Board Works

Created by legislation in 2019, the Maryland Prescription Drug Affordability Board operates similarly to a state utility commission. Its mission is to evaluate and address high-cost prescription drugs that strain public and private healthcare budgets. The board has the power to set upper payment limits, or price caps, on specific medications for certain payer segments. It focuses on drugs where price increases outpace inflation or where costs pose a significant barrier to access.

The Board's Process for Setting Caps

Before imposing a cap, the board conducts extensive analysis, including reviewing drug pricing data, manufacturer costs, and patient outcomes. It also considers public input from stakeholders such as patients, insurers, and pharmaceutical companies. The goal is to establish a fair price that ensures affordability without jeopardizing drug availability. For Ozempic, the board benchmarked the cap against what Medicare pays, as that is considered a reasonable reference point.

Details of the Ozempic Price Cap Decision

The board agreed to set an upper payment limit at $274 for a 30-day supply of Ozempic. This price applies to purchases made by state and local governments in Maryland. According to Andrew York, the board's executive director, the expected cost was tied to the maximum fair price paid by Medicare for the same medication. The board estimates that this cap will save the state and local entities approximately $5.8 million per year once fully implemented by January 2027.

Benchmarking Against Medicare

Using Medicare's negotiated prices as a benchmark ensures that the cap aligns with what the federal government deems reasonable. Medicare uses its purchasing power to secure lower rates, and the Maryland board has adopted a similar approach. This methodology provides a transparent and data-driven basis for the cap, reducing the risk of legal challenges from drug manufacturers.

Expected Savings for Maryland

The $5.8 million in annual savings primarily comes from reducing the state's own healthcare spending on Ozempic for employees and retirees. Additionally, local governments—including counties and municipalities—will benefit from lower prescription costs. The board's analysis suggests that without intervention, Ozempic prices would continue to rise, making the cap a proactive measure to stabilize expenses.

Expansion to Commercial Insurance by 2028

Looking ahead, the Maryland board plans to extend its authority to the broader commercial insurance market. Starting in 2028, it will begin setting upper payment limits on high-cost drugs purchased by all Maryland residents, not just those covered by government plans. This expansion could affect millions of people in the state, potentially lowering out-of-pocket costs for patients with private insurance. The board will likely face resistance from pharmaceutical companies and insurers, but it has legal backing to proceed.

Broader Implications for Drug Pricing Policy

Maryland's actions serve as a test case for other states considering similar affordability boards. By capping Ozempic, the board is signaling that it will tackle expensive, widely used drugs that contribute to rising healthcare costs. This could pressure drug makers to reconsider their pricing strategies or offer rebates to avoid formal caps. The success of the Maryland model may encourage federal policymakers to explore similar mechanisms at the national level. However, the board must ensure that caps do not lead to shortages or reduced innovation, as critics warn.

What This Means for Patients

For patients with diabetes who rely on Ozempic, the cap means lower prices for those covered by state and local government plans. Once expanded to commercial insurance in 2028, many more Maryland residents could see reduced costs. However, the board's actions primarily affect payers, and the savings may not fully pass through to individual patients if insurers do not adjust copayments. The board plans to monitor this closely.

Conclusion: A Pioneering Step in Drug Cost Control

The Maryland Prescription Drug Affordability Board's decision to cap Ozempic at $274 per 30-day supply represents a bold move to contain healthcare spending. By leveraging public purchasing power and benchmarking against Medicare, the board aims to save millions while ensuring patients remain protected from excessive drug prices. As the board prepares to expand its reach to commercial insurance, all eyes will be on Maryland as a leader in prescription drug affordability. The outcome of this experiment could shape future state and national policies on drug pricing.

Note: This article is based on information available from the Maryland Prescription Drug Affordability Board and related reports.

Tags: